²é¿´: 3473  |  »Ø¸´: 4
µ±Ç°Ö÷ÌâÒѾ­´æµµ¡£
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

ÒÁ´¨µ¤

гæ (³õÈëÎÄ̳)

[½»Á÷] Advanced MaterialsµÄͶ¸å¸ñʽ£¬ÔõÑùÔÚAdvanced MaterialsÉÏͶ¸å

Advanced MaterialsµÄͶ¸å¸ñʽ£¬ÔõÑùÔÚAdvanced MaterialsÉÏͶ¸å£¿
»Ø¸´´ËÂ¥

» ÊÕ¼±¾ÌûµÄÌÔÌûר¼­ÍƼö

Ñô¹â½×ÌÝ

» ²ÂÄãϲ»¶

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

ciacyang

Ìú¸Ëľ³æ (ÕýʽдÊÖ)

¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
Ê×Ïȵ½WileyÖ÷Ò³µÄmanuscriptXpressÉÏÈ¥×¢²á£¬È»ºóÔÙµ½Adv. Mater.Ö÷Ò³ÉÏÕÒµ½CommunicationµÄÄ£°å£¬ÌíÈëÏàÓ¦ÄÚÈݼ´¿É¡£ÏÂÔØAMµÄ1ƪÎÄÕ¼°Supporting informationÔÙ×ÐϸÑо¿Ò»ÏÂͼ±íµÄ¸ñʽ£¡
4Â¥2009-11-25 17:03:54
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 5 ¸ö»Ø´ð

ygd

Ìú¸Ëľ³æ (ÕýʽдÊÖ)

¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
°ïÄã¶¥ÁË£¬²»¹ýÎÒûͶ¹ýÕâô¸ßµÄ£¬ÏÖÔÚÓÐÒ»¸öºÃµÄidea,Õý¿¼ÂÇͶÏòÕâ¸ö¿¯Îï
·¸Ç¿ººÕß,ËäÔ¶±ØÖï!
2Â¥2009-11-22 05:38:40
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

ÒÁ´¨µ¤

гæ (³õÈëÎÄ̳)

ÓйØSCI

SCI£¨ Science Citation Index £©£ºÊÇÃÀ¹úISI£¨Institute for scientific Information£©Ê¹ÓõĶԿƼ¼¿¯ÎïºÍÂÛÎĽøÐÐÆÀ¼ÛµÄÒ»ÖÖ¹¤¾ß¡£ÊÕ¼Լ3600ÖÖºËÐÄ¿¯ÎÆäÖÐ1000ÓàÖÖΪÉúÃüѧ¿ÆÔÓÖ¾¡£
IF (Impact Factors)£ºÊÇij¿¯ÎïÁ½ÄêÖÐÂÛÎı»ÒýÓÃÊýÓë¿ÉÒÔ±»ÒýÓõÄÂÛÎÄÊýÖ®±È¡£
• Ö÷Òª·´Ó³½üÁ½ÄêÂÛÎı»ÒýÓÃÇé¿ö¡£
• ²»Í¬Ñ§¿Æ²»ÄÜÓÃÀ´±È½Ï¡£
• ²»Í¬ÀàÐÍ¿¯ÎïÒ²²»ÄÜÓÃÀ´±È½Ï¡£
ÂÛÎĵÄÖÊÓëÁ¿
• SCIÎÄÕµÄÊýÁ¿£¨¹úÄÚ¶àÊýµ¥Î»×¢ÒâµÄÊÇÁ¿£©
• IF£¨¹ú¼ÊÉÏËù¿´ÖصÄÊÇÖÊ£©
• SCIÎÄÕÂÊý¡ÁIF¡ú ¼ÓȨ£¬¸üÄÜ¿Í¹ÛÆÀÅиöÈËËù×÷µÄ¿ÆÑ§¹±Ïס£

¹ÄÀøÏò¹úÍâͶ¸å
• ¹úÄÚºËÐÄ¿¯Îï°æÃæÓÐÏÞ£¬Í¶¸åÈ˶ࣻ
• ¹úÄÚ¿¯ÎïSCIÊÕ¼ÔÓÖ¾ÂÛÎÄ·¢±í¸üΪÀ§ÄÑ£»
• ¹úÄÚ¿¯ÎïÓ°ÏìÖ¸Êý¶¼½ÏµÍ£»
• ´ó¶àÊý¹ú¼Ê¿¯ÎïûÓаæÃæ·Ñ£»
• ¹ú¼Ê¿¯Îï´ÓËÍÉóµ½·¢±íʱ¼äÖÜÆÚ¶Ì¡£
ÈçºÎÔÚSCI·¢±íÂÛÎÄ
• Ñ¡Ì⣺ºÃµÄ idea £¬ÐÂÓ±£¬½²¾¿¿ÆÑ§ÒâÒ壬±ÜÃâ¼òµ¥Öظ´Ñо¿¡£
• Ñ¡ÔñÊʺϿ¯ÎïͶ¸å¡£
•Ê×ÏÈ´ÓÔÓÖ¾µÄhomepageÉÏÏÂÔØInstruction for Author£¬°´ÕÕͶ¸åÒªÇó£¬ÈçÔÚͶ¸åµÄ·ÝÊý¡¢ÂÛÎÄÌåÀý¡¢³¤¶È¡¢Í¼±í¡¢²Î¿¼ÎÄÏ×µÄÒýÓ÷½·¨¡¢Åäͼ˵Ã÷£¨Figure legends£©µÈ£¬ÖðÌõ×ñÑ­ÔÓÖ¾ÉçÒªÇó¡£

ÈçºÎ×¼±¸¸å¼þ
•Letter to editor-in-chief : ¢ÙÉùÃ÷ÎĸåȨתÈ㻢Úδһ¸å¶àͶ£¬ºÍÔÚ¸å¼þδ×÷³ö¾ö¶¨Ç°²»×¼±¸Ò»¸å¶àͶ£»¢ÛËùÓÐÁгö×÷Õß¾ù¶ÔÎĸåÓÐÈ·Çй±Ï×£»¢ÜÎĸåÄÚÈÝÕæÊµ£¬ÎÞ×÷α£»¢ÝËùÓÐ×÷Õß¾ùÒÑÔĶÁÎĸ壬ÇÒͬÒâË͸壻¢ÞͨÐÅ×÷ÕßµØÖ·¡¢µç»°¡¢ Fax ¡¢ e-mail£»¢ßͨÐÅ×÷ÕßµÄÇ©Ãû¡£

ÈçºÎ×¼±¸¸å¼þ
• Title page
• Abstract£º
• Text : Introduction£» Methods£» Results£» Discussion£»
• References£»
• Acknowledgements

• Figure legends
• Tables and Figures

ÈçºÎ×¼±¸¸å¼þ
• ʹÓÃÇåÎúºÏÀíµÄÓïÑÔ£¬±ÜÃâÐÞÊδʣ¨Èç×îºÃ¡¢µÚÒ»£©ºÍÉçÂÛÐÔÓïÑÔ£¨ÈçÁîÈ˾ªÒìµØ¡¢ÁîÈ˸ÐÐËȤµØµÈ£©¡£
• ÂÛÎÄÌâĿӦÐÑÄ¿£¬Çå³þ±í´ï¶ø²»ÒªÊ¹Óú¬ºýµ¥´Ê¡£
¡¡¡¡Èç±ÜÃâʹÓ㺡Á¡Á Ò©Îï¶Ô¼±ÐÔÐĹ£Ãæ»ýµÄÓ°Ïì¡¡
¡¡¡¡²»ÈçʹÓ㺡Á¡Á Ò©ÎïËõС¼±ÐÔÐĹ£Ãæ»ý
• ½éÉÜÑо¿±³¾°Ê®·ÖÖØÒª£¬ÒªÇå³þ±í´ïΪʲôҪ½øÐб¾Ñо¿£¬³¤¶ÈÒ»°ãÔÚÒ»¸öpageÄÚ£¬ÒýÓÃÎÄÏ×Ò»°ãÔÚ15ÌõÄÚ¡£
• ·½·¨Ñ§ÖÐÒ»¶¨ÒªËµÃ÷£ºÁÙ´²Ñо¿Óв¡ÈËÖªÇéͬÒ⣬ͨ¹ýÂ×ÀíίԱ»áÅú×¼£»¶¯ÎïʵÑé·ûºÏ±¾´óѧµÄ¶¯Îï¹ÜÀíÓ붯ÎïʵÑéµÄÕ³̵ȡ£
• ÌØ±ð×¢Òâ·½·¨Ñ§ÊÇ·ñºÏÀí£¬±¾·½·¨ÊÇ·ñĿǰ¹ú¼ÊÉÏͨÓã»
• ½á¹ûÊÇÎÄÕÂÖÐ×îÎªÖØÒª²¿·Ö£¬ÇåÎúµÄͼ¼þ¡¢±í¸ñ£¬ºÏÀíµÄ½á¹û½âÊ͵ȣ»
• ÌØ±ð×¢Òâ·½·¨Ñ§¡¢½á¹ûÖпÉÄܵÄСµÄ©¶´£¬×îºÃÇë¶àλͬÐÐר¼ÒÉóÔÄ¡£
• Discussion²¿·ÖÖ»¶Ô±¾ÎĽá¹û½øÐÐÌÖÂÛ£¬ÓëͬÀàÑо¿½á¹û½øÐбȽϡ£¶ÔÎÄÖнá¹ûÉæ¼°µÄ¿ÉÄÜ»úÖÆ²»ÒªÕ¹¿ªÌÖÂÛÌ«¶à£¬²»Òª½øÐÐÍÆÀíÌÖÂÛ£»
• ×¢Òâ½áÂÛÓ¦¿Í¹Û£¬²»Òª¿ä´ó
•²Î¿¼ÎÄÏ×ÒýÓÃÓ¦¾¡Á¿ÓÃ×îУ»
• ×¢Òâ²Î¿¼ÎÄÏ׸ñʽ£»
• ÈçÓпÉÄÜ£¬¾¡¿ÉÄÜÒýÓÃÄâͶ¿¯Îï½ü2ÄêµÄ·¢±íÎÄÕ¡£
•³É¸åÒÔºó¾¡Á¿ÇëͬÐÐר¼Ò·´¸´Ð޸ģ»
•¿ÉÇëÓïÑÔר¼Ò°ïÖú¾ÀÕýÓï·¨´íÎó£»
•ÎðÒ»¸å¶àͶ£¬ºÜ¶àʱºòÓпÉÄÜ»áËÍÖÁͬһר¼ÒÉóÔÄ¡£ ¸å¼þµÄÐÞ»Ø
•Ò»°ãÀ´Ëµ£¬´ÓÖ÷±àµÄ»ØÐźÍÉó¸åÈË(reviewer)µÄÐÞ»ØÒâ¼û¿É¿´³öÎÄÕ¼ÓõĿÉÄÜÐÔÓжà´ó¡£Ö÷±àµÄ»ØÐÅ»áÌØ±ðÌáµ½ÄãµÄÎÄÕµĿÆÑ§ÏȽøÐÔ(scientific priority)£»Éó¸åÈ˶ÔÎÄÕµÄ×ܵįÀ¼ÛÖлáÌáµ½¶ÔÎÄÕÂÊÇ·ñ¸ÐÐËȤ(interesting)µÈ£»
•Ð޻ز»Òª²Ö´Ù£¬·´¸´ÔĶÁ¡¢Àí½âÉó¸åÈËËùÌá³öµÄÎÊÌâ¡£

¸å¼þµÄÐÞ»Ø
•¶ÔÿλÉó¸åÈËÌá³öµÄÒâ¼û£¬ÒªÖðÌõ×÷»Ø´ð(response to reviewer1£¬2£¬3)£»
•¶ÔÐ޻ظåÖÐÒÑ×÷Ð޸ĵĵط½Òª¾ßÌå±êÃ÷(page, lines)£»
•¸øÖ÷±à»ØÐÅ£¬¸Ðл¸øÎĸåÌá³öµÄÐÞ¸ÄÒâ¼û£¬²¢Ö¸³ö°´Ð޸Ľ¨ÒéÒÑ×÷µÄÐ޸ģ¬Î´×÷Ð޸ĵĵط½Çë˵Ã÷ÀíÓÉ¡£
Title page µÄʽÑù£º

Peroxisome Proliferation-Activated Receptor-g Ligands Ameliorate Experimental Autoimmune Myocarditis

Zuyi Yuan, MD, PhD; Yan Liu, MD; Yu Liu, MD; Jijun Zhang, MD; Chiharu Kishimoto, MD, PhD*; Yanni Wang, MD; Aiqun Ma, MD, PhD; Zhiquan Liu, MD.
Department of Cardiovascular Medicine, First Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China; *Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan

First author's surname: Yuan
Running head: PPARg ligands ameliorate myocarditis

Supported by Natural Science Foundation of China (30170371)

Address correspondence to:
Zuyi Yuan, MD, PhD
Department of Cardiovascular Medicine, First Hospital of Xi'an Jiaotong University,
No.1 Jiankang Road, Xi'an, Shaanxi 710061, China
Tel: +86-29-532-4021 Fax: +86-29-5263190
3Â¥2009-11-25 09:59:42
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

llp8003581

ÖÁ×ðľ³æ (ÖøÃûдÊÖ)

¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
¼ûʶÁË£¬Ð»Ð»2Â¥µÄ³æÓÑ
5Â¥2009-11-27 00:56:24
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] Çó²ÄÁϵ÷¼Á +8 ¸ô±Ú³ÂÏÈÉú 2026-03-12 8/400 2026-03-18 22:19 by li123456789.
[¿¼ÑÐ] Ò»Ö¾Ô¸»ªÖпƼ¼´óѧ£¬080502£¬354·ÖÇóµ÷¼Á +4 ÊØºòϦÑôCF 2026-03-18 4/200 2026-03-18 22:16 by li123456789.
[¿¼ÑÐ] Ò»Ö¾Ô¸¼ªÁÖ´óѧ²ÄÁÏѧ˶321Çóµ÷¼Á +4 Ymlll 2026-03-18 6/300 2026-03-18 22:15 by li123456789.
[¿¼ÑÐ] 085410È˹¤ÖÇÄÜר˶317Çóµ÷¼Á£¨0854¶¼¿ÉÒÔ£© +3 xbxudjdn 2026-03-18 3/150 2026-03-18 22:14 by zhq0425
[¿¼ÑÐ] 295Çóµ÷¼Á +3 Ò»Ö¾Ô¸¾©Çø211 2026-03-18 5/250 2026-03-18 17:03 by zhaoqian0518
[¿¼ÑÐ] 085601ר˶£¬×Ü·Ö342Çóµ÷¼Á£¬µØÇø²»ÏÞ +5 share_joy 2026-03-16 5/250 2026-03-18 14:48 by haxia
[¿¼ÑÐ] 297Çóµ÷¼Á +8 Ï·¾«µ¤µ¤µ¤ 2026-03-17 8/400 2026-03-18 14:30 by laoshidan
[¿¼ÑÐ] 302Çóµ÷¼Á +10 ºôºôºô¡£¡£¡£¡£ 2026-03-17 10/500 2026-03-18 12:45 by Linda Hu
[¿¼ÑÐ] ÉúÎïѧ071000 329·ÖÇóµ÷¼Á +3 ÎÒ°®ÉúÎïÉúÎﰮΠ2026-03-17 3/150 2026-03-18 10:12 by macy2011
[¿¼ÑÐ] 293Çóµ÷¼Á +11 zjlµÄºÅ 2026-03-16 16/800 2026-03-18 08:10 by zhukairuo
[»ù½ðÉêÇë] ±»ÎÒÑÔÖУºÐÂÄ£°å²»Ç¿µ÷¸ñʽÁË£¬¼Ùר¼Ò¿ªÊ¼¹Ü¸ñʽÁË +4 beefly 2026-03-14 4/200 2026-03-17 22:04 by »ÆÄñÓÚ·ÉChao
[˶²©¼ÒÔ°] ºþ±±¹¤Òµ´óѧ ÉúÃü¿ÆÑ§Ó뽡¿µÑ§Ôº-¿ÎÌâ×éÕÐÊÕ2026¼¶Ê³Æ·/ÉúÎï·½Ïò˶ʿ +3 1ϲ´º8 2026-03-17 5/250 2026-03-17 17:18 by ber´¨cool×Ó
[¿¼ÑÐ] 304Çóµ÷¼Á +4 ahbd 2026-03-14 4/200 2026-03-16 16:48 by ÎҵĴ¬Îҵĺ£
[¿¼ÑÐ] 0703»¯Ñ§µ÷¼Á 290·ÖÓпÆÑо­Àú£¬ÂÛÎÄÔÚͶ +7 ÄåÄågk 2026-03-14 7/350 2026-03-16 10:12 by houyaoxu
[¿¼ÑÐ] Öпƴó²ÄÁÏר˶319Çóµ÷¼Á +3 ÃÏöβÄÁÏ 2026-03-13 3/150 2026-03-14 18:10 by houyaoxu
[¿¼ÑÐ] 297Çóµ÷¼Á +4 ѧº£Æ¯²´ 2026-03-13 4/200 2026-03-14 11:51 by ÈÈÇéɳĮ
[¿¼ÑÐ] Çó²ÄÁϵ÷¼Á 085600Ó¢Ò»Êý¶þ×Ü·Ö302 ǰÈý¿Æ235 ¾«Í¨»úÆ÷ѧϰ Ò»Ö¾Ô¸¹þ¹¤´ó +4 ÁÖyaxin 2026-03-12 4/200 2026-03-13 22:04 by ÐÇ¿ÕÐÇÔÂ
[¿¼ÑÐ] 0703»¯Ñ§Çóµ÷¼Á +7 Â̶¹ÇÛ²ËÌÀ 2026-03-12 7/350 2026-03-13 17:25 by njzyff
[¿¼ÑÐ] Çóµ÷¼Á +3 ³ÌÓ꺼 2026-03-12 3/150 2026-03-13 15:06 by JourneyLucky
[¿¼ÑÐ] ÍÁľµÚÒ»Ö¾Ô¸276Çóµ÷¼Á£¬¿ÆÑкͼ¼ÄÜÊ®·Ö·á¸»£¬ÇóÐÂÐË·½ÏòµÄµ¼Ê¦ÊÕÁô +3 ÍÁľСÌì²Å 2026-03-12 3/150 2026-03-13 15:01 by JourneyLucky
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û